You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

List of Excipients in API dexlansoprazole


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing dexlansoprazole

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
TWI PHARMACEUTICALS INC DEXLANSOPRAZOLE dexlansoprazole 24979-703 ALUMINUM OXIDE
TWI PHARMACEUTICALS INC DEXLANSOPRAZOLE dexlansoprazole 24979-703 CARRAGEENAN
TWI PHARMACEUTICALS INC DEXLANSOPRAZOLE dexlansoprazole 24979-703 FD&C BLUE NO. 2
TWI PHARMACEUTICALS INC DEXLANSOPRAZOLE dexlansoprazole 24979-703 FERRIC OXIDE RED
TWI PHARMACEUTICALS INC DEXLANSOPRAZOLE dexlansoprazole 24979-703 HYDROXYPROPYL CELLULOSE
TWI PHARMACEUTICALS INC DEXLANSOPRAZOLE dexlansoprazole 24979-703 HYPROMELLOSE
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Sign Up

Excipients in ANDA-approved (generic) drugs containing dexlansoprazole

Company Ingredient NDC Excipient
Mylan Pharmaceuticals Inc dexlansoprazole 0378-2085 CARRAGEENAN
Mylan Pharmaceuticals Inc dexlansoprazole 0378-2085 ETHYLCELLULOSE AQUEOUS DISPERSION TYPE B
Mylan Pharmaceuticals Inc dexlansoprazole 0378-2085 FD&C BLUE NO. 2
Mylan Pharmaceuticals Inc dexlansoprazole 0378-2085 FERROSOFERRIC OXIDE
Mylan Pharmaceuticals Inc dexlansoprazole 0378-2085 GLYCERYL MONO AND DIPALMITOSTEARATE
Mylan Pharmaceuticals Inc dexlansoprazole 0378-2085 HYPROMELLOSE
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Sign Up

Detailed excipient profiles for dexlansoprazole

Excipient focus: ALUMINUM OXIDE

Excipient focus: AMMONIA

Excipient focus: BUTYL ALCOHOL

Excipient focus: CALCIUM HYDROXIDE

Excipient focus: CARRAGEENAN

Excipient focus: D&C YELLOW NO. 10

Excipient focus: ETHYLCELLULOSE AQUEOUS DISPERSION TYPE B

Excipient focus: FD&C BLUE NO. 1

Excipient focus: FD&C BLUE NO. 2

Excipient focus: FD&C RED NO. 40

Excipient focus: FD&C YELLOW NO. 5

Excipient focus: FD&C YELLOW NO. 6

Excipient focus: FERRIC OXIDE RED

Excipient focus: FERROSOFERRIC OXIDE

Excipient focus: GLYCERYL MONO AND DIPALMITOSTEARATE

Excipient focus: HYDROXYPROPYL CELLULOSE

Excipient focus: HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED

Excipient focus: HYPROMELLOSE

Excipient focus: HYPROMELLOSE 2910

Excipient focus: HYPROMELLOSES

Excipient focus: ISOPROPYL ALCOHOL

Excipient focus: LAURYL SULFATE

Excipient focus: LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE

Excipient focus: MAGNESIUM CARBONATE

Excipient focus: MANNITOL

Excipient focus: METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER

Excipient focus: METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER

Excipient focus: METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER

dexlansoprazole drug variants not containing METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER

Company Ingredient NDC
Mylan Pharmaceuticals Inc dexlansoprazole 0378-2085
TWI PHARMACEUTICALS INC dexlansoprazole 24979-001
A-S Medication Solutions dexlansoprazole 50090-4374
A-S Medication Solutions dexlansoprazole 50090-5944
A-S Medication Solutions dexlansoprazole 50090-5956
A-S Medication Solutions dexlansoprazole 50090-6514
>Company >Ingredient >NDC

Subscribe to access the full database, or Sign Up

Excipient focus: METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER

Excipient focus: POLYETHYLENE GLYCOL

Excipient focus: POLYETHYLENE GLYCOL 6000

Excipient focus: POLYETHYLENE GLYCOL 8000

Excipient focus: POLYSORBATE 80

Excipient focus: POTASSIUM CHLORIDE

Excipient focus: POTASSIUM HYDROXIDE

Excipient focus: POVIDONE

Excipient focus: PROPYLENE GLYCOL

Excipient focus: SHELLAC

Excipient focus: SILICON DIOXIDE

Excipient focus: SODIUM HYDROXIDE

Excipient focus: STARCH, CORN

Excipient focus: SUCROSE

Excipient focus: TALC

Excipient focus: TITANIUM DIOXIDE

Excipient focus: TRIETHYL CITRATE

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
 NCE-1 Patent Challenge Dates 2024 - 2025
 Trigger-based marketing for the life sciences
 Get DrugPatentWatch Business Intelligence Reports at Amazon.com
 DrugChatter - AI-based answers to questions about drugs
 RxJam - Digital Marketing for Life Sciences
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group